ArticleAsian journal of transfusion science
Efficacy of plerixafor in CD34+ stem cell mobilization in healthy pediatric stem cell donors.
Article in Asian journal of transfusion science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesEfficient stem cell collection from pediatric donors is a common challenge for allogeneic hematopoietic stem cell transplants (HSCT). The addition of plerixafor, a CXCR4 antagonist to standard stem cell mobilization regimens has shown success. We describe our experience with the usage of a single dose of plerixafor in addition to granulocyte colony-stimulating factor (G-CSF) in healthy pediatric stem cell donors for patients undergoing HSCT. MATERIALS AND
methodsA retrospective review of the safety and efficacy of plerixafor, used in pediatric stem cell donors for aiding stem cell mobilization, was done. Data from 14 pediatric donors who received plerixafor in addition to standard G-CSF were studied.
resultsPlerixafor was well tolerated by all donors with no major adverse effects. All donors showed robust peripheral blood stem cell mobilization, enabling an adequate stem cell collection with single apheresis, even in scenarios with an unfavorable donor/patient body weight ratio.
conclusionThe use of plerixafor can be encouraged in pediatric donors to optimize apheresis outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.